Table 2 Comparison of the EGFR and KRAS mutation status in the tumor tissue and plasma
Plasma EGFR mutation status | |||||||||
Tissue EGFR mutation status | Positive | Negative | Total | ||||||
Positive | 34 | 17 | 51 | ||||||
Negative | 18 | 125 | 143 | ||||||
Total | 52 | 142 | 194 | ||||||
G719A | 19DEL | L858R | T790M | Exon20ins | S768I | Multiple | Wild | Total | |
G719A | 0 | ||||||||
19DEL | 21 | 1 | 1 | 1 | 14 | 38 | |||
L858R | 9 | 1 | 3 | 13 | |||||
T790M | 0 | ||||||||
exon20ins | 0 | ||||||||
S768I | 0 | ||||||||
Multiple | 0 | ||||||||
Wild type | 3 | 3 | 7 | 2 | 3 | 125 | 143 | ||
Total | 0 | 24 | 13 | 8 | 2 | 1 | 4 | 142 | 194 |
N | % (95 % CI) | ||||||||
Concordance | 159 | 82.0 (76.5–87.4) | |||||||
Sensitivity | 34 | 66.7 (60.0–73.3) | |||||||
Specificity | 125 | 87.4 (82.7–92.1) | |||||||
PPV | 52 | 65.4 (58.7–72.1) | |||||||
NPV | 142 | 88.0 (83.5–92.6) | |||||||
Plasma KRAS mutation status | |||||||||
Tissue KRAS mutation status | Positive | Negative | Total | ||||||
Positive | 6 | 6 | 12 | ||||||
Negative | 13 | 110 | 123 | ||||||
Total | 19 | 116 | 135 | ||||||
Codon 12 | Codon 13 | Codon 59 | Codon 61 | Codon 12/61 | Wild | Total | |||
Codon 12 | 3 | 5 | 8 | ||||||
Codon 13 | 1 | 1 | 2 | ||||||
Codon 59 | |||||||||
Codon 61 | 1 | 1 | 2 | ||||||
Codon 12/61 | |||||||||
Wild type | 10 | 2 | 1 | 110 | 123 | ||||
Total | 13 | 1 | 1 | 3 | 1 | 116 | 135 | ||
N | % (95 % CI) | ||||||||
Concordance | 116 | 85.9 (80.1–91.8) | |||||||
Sensitivity | 6 | 50.0 (41.6–58.4) | |||||||
Specificity | 110 | 89.4 (84.2–94.6) | |||||||
PPV | 19 | 31.6 (23.7–39.4) | |||||||
NPV | 116 | 94.8 (91.1–98.6) | |||||||